



The Role of Alternative Splicing in Cancer

Guest Editor:

Prof. Dr. Luis Franco

1. Department of Biochemistry and Molecular Biology, Universitat de València, 46010 Valencia, Spain

2. Department of Oncology, Institute of Health Research INCLIVA, 46010 Valencia, Spain

Deadline for manuscript submissions:

closed (15 May 2023)

Message from the Guest Editor

Dear Colleagues,

Since the original discovery in 1994 that the canonical isoform of the *FAS* gene bound to the mitochondrial membrane is pro-apoptotic, while a soluble isoform is anti-apoptotic, many examples of alternative splicing have been found in which both oncogenic and suppressor isoforms may be produced from the same gene. Aberrant splicing may, therefore, result in oncogenicity in otherwise normal tissue. Due to these circumstances, a great interest in the relationships between alternative splicing and cancer has arisen in the last few years.

I am pleased to invite you to contribute to this Special Issue of *Cancers*, which tries to gather relevant papers supporting the increasing importance of those relationships. Both reviews and original manuscripts on mechanisms of alternative splicing, detection and analysis of isoforms, their value as diagnostic and/or prognostic factors, and splicing-related therapeutic approaches will be welcome. We hope that both basic and clinical oncologists will be interested in this exciting field of cancer research.

We are looking forward to receiving your contributions.

Prof. Dr. Luis Franco
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)